Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
City Therapeutics Unveils CITY-RBP4 RNAi Data for Stargardt at ARVO 26
City Therapeutics presented preclinical data at ARVO 2026 for CITY-RBP4, an RNAi therapy showing potent RBP4 silencing to treat Stargardt disease type 1.
NanoViricides' NV-387 Granted FDA Orphan Drug Status for Measles Target
The FDA granted NanoViricides' NV-387 Orphan Drug Designation for measles, providing seven years of market exclusivity and potential priority review benefits.
Evotec and Almirall Nominate First Preclinical Dermatology Candidate
Evotec and Almirall announce their first preclinical development candidate for immune-mediated skin diseases, leveraging an advanced AI discovery platform.
FDA Grants Breakthrough Status to Terns Pharma's CML Therapy TERN-701
The FDA has awarded breakthrough therapy designation to TERN-701 for chronic myeloid leukemia, following Merck's $6.7 billion acquisition of Terns Pharma.
Can-Fite's Namodenoson Yields Positive Data in Pancreatic Cancer Trial
Can-Fite reports promising Phase 2 data for namodenoson in advanced pancreatic cancer, showing durable disease stabilization and a strong safety profile.
Clene Advances ALS Drug CNM-Au8 Toward Accelerated FDA NDA Submission
Clene Inc. plans an accelerated FDA NDA filing for its ALS drug CNM-Au8 by Q3 2026, driven by NfL biomarker data and aiming to address urgent patient needs.
Enveric's EB-003 Shows Positive Preclinical Results for PTSD Treatment
Enveric Biosciences highlights positive preclinical data for EB-003 in PTSD models, showing rapid reduction in fear response without hallucinogenic effects.
BeOne Signs $2B Deal for Preclinical Trispecific Antibody from Huahui
BeOne Medicines pays $20M upfront for an option to buy Huahui Health's preclinical trispecific antibody HH160, with potential milestones up to $1.9B.
FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Care
The US FDA authorizes an early access program for Revolution Medicines' daraxonrasib (RMC-6236) for patients with previously treated pancreatic cancer.
FDA Approves Vepdegestrant for ESR1-Mutant Advanced Breast Cancer Therapy
The FDA has approved vepdegestrant (ARV-471), the first PROTAC degrader, for patients with ESR1-mutated advanced breast cancer based on VERITAC-2 data.
UCB Data at AAN 2026 Highlights Psychosocial Impacts of Epilepsy on Life
UCB presents new data highlighting the profound impact of epilepsy, sleep disruption, and prolonged seizures on patients and caregivers at AAN 2026.
Phase 3 Trial of Synthetic Hypericin for CTCL Halted Early for Futility
Soligenix's Phase 3 FLASH2 trial of synthetic hypericin for cutaneous T-cell lymphoma (CTCL) stopped for futility. Read full details and prior trial data.
16
17
18
19
20
21
22
23
24
